Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review
Purpose: Livedoid vasculopathy (LV) is a chronic microvascular thrombosis disorder with an unclear pathogenesis, potentially involving hypercoagulability and inflammation. This systematic review aims to evaluate the efficacy and safety of Janus kinase (JAK) inhibitors and biologics in the treatment...
Saved in:
Main Authors: | Yu Liu, Tingting Li, Wei Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2025-12-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2025.2451804 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Baricitinib Successfully Treated a Teenager with Refractory Livedoid Vasculopathy: A Case Report and Literature Review
by: Liu C, et al.
Published: (2025-02-01) -
Livedoid vasculopathy with mononeuritis multiplex associated with protein S deficiency mimicking systemic vasculitis
by: Vikramraj K Jain, et al.
Published: (2019-01-01) -
Increased risk of Pneumocystis jirovecii colonization in rheumatoid arthritis patients on biologics and Janus kinase inhibitor
by: Ya-Chun Huang, et al.
Published: (2025-02-01) -
Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis
by: Grace Xiong, BHSc, et al.
Published: (2025-04-01) -
Screening for Janus kinase-2 exon 12 mutations among Janus kinase-2 V617F-negative polycythemia vera suspected Iraqi patients
by: Mushtaq M. Khazeem, et al.
Published: (2024-12-01)